Previous 10 | Next 10 |
DLA Piper advises Histogen in its US$14 million upsized public offering PR Newswire NEW YORK , Jan. 7, 2021 /PRNewswire/ -- DLA Piper represented advised Histogen, Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potentia...
SAN DIEGO, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today an...
SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (Nasdaq: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today announced that...
Gainers: Hoth Therapeutics (HOTH) +49%. Bionano Genomics (BNGO) +38%. Clearside Biomedical (CLSD) +17%. Regional Health Properties (RHE) +14%. Ampio Pharmaceuticals (AMPE) +13%.Losers: Histogen (HSTO) -26%. Novan (NOVN) -22%. ORIC Pharmaceuticals (ORIC) -14%. DermTech (DMTK) -12%. T...
Histogen (HSTO) priced a public offering of 14M shares along with accompanying warrants at an effective public offering price of $1.00/share.Warrants have an exercise price of $1.00/share, are immediately exercisable, and expire five years following issuance date.Gross proceeds...
SAN DIEGO, Dec. 30, 2020 (GLOBE NEWSWIRE) -- Histogen Inc. (Nasdaq: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today announced that...
uniQure (QURE) -18% after the FDA clinical hold on its hemophilia B gene therapy program, including the pivotal, Phase 3 HOPE-B study.MingZhu Logistics Holdings Limited (YGMZ) -11%.CYREN (CYRN) -13%.Transocean (RIG) -11%.The9 (NCTY) -11%.DBV Technologies (DBVT) -11%.FibroG...
Histogen ([[HSTO]] -4.0%) has submitted an Investigational New Drug ((IND)) application with the FDA for the initiation of a Phase 1/2 trial to evaluate HST-003, extracellular matrix.The study will assess the safety and efficacy of human implanted within microfracture int...
Phase 1/2 Trial Initiation for Knee Cartilage Regeneration Anticipated in First Quarter 2021 $2M Grant Awarded by the Department of Defense in September 2020 to Support Clinical Development SAN DIEGO, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical...
Micro-cap Histogen ([[HSTO]] +173.4%) after announcing preliminary week 18 results from its Phase 1b/2a trial evaluating HST-001 in androgenic alopecia (male pattern baldness).At the week 18 primary efficacy endpoint, patients treated with HST-001 demonstrated separation from placebo for...
News, Short Squeeze, Breakout and More Instantly...
DS Smith Plc. (DITHF) is expected to report for Q4 2024 Bluegreen Vacations Holding Corporation - Class B (BVHBB) is expected to report for Q1 2024 Harbour Energy Plc ADR (HBRIY) is expected to report for Q1 2024 Bayerische Motoren Werke AG (BAMXF) is expected to report for Q1 2024 ...
Usinas Siderurgicas De Minas Gerais S.A. ADR (Representing Pref Share Cl A) (USNZY) is expected to report $0 for Q2 2024 CREATD INC. (CRTD) is expected to report for Q1 2024 Bluegreen Vacations Holding Corporation - Class B (BVHBB) is expected to report for Q1 2024 Senstar Technologie...
Verbund AG ADR (OEZVY) is expected to report for Q1 2024 Rent the Runway Inc. (RENT) is expected to report $-6.56 for Q1 2025 Johnson Matthey plc ADR (JMPLY) is expected to report for Q4 2024 RVL Pharmaceuticals plc (RVLPQ) is expected to report for Q1 2024 Ciena Corporation (CIEN...